Nuwellis Prices $3.4M At-The-Market Offering at $2.59, Adding to Dilution Woes
NUWE is trading near its 52-week low of $1.83 (7.7% above the low) on elevated volume (54× avg).
Summary
Nuwellis priced a $3.4 million registered direct offering at $2.59 per share, at-the-market under Nasdaq rules. This follows a series of dilutive financings, including a $6.0 million deeply discounted offering in June and a recent 1-for-35 reverse split. The company remains under severe financial strain with a going concern warning and a market cap of just $1.6 million. The offering, while at market, further dilutes existing shareholders and signals ongoing cash needs. Shareholders recently rejected a proposal to authorize shares for warrant exercises, adding uncertainty to future capital raises.
Updates
· SEC 424B5 — The offering includes 1,310,890 shares and concurrent private placement warrants for 1,310,890 shares at $2.59, exercisable for five years. Ladenburg Thalmann is placement agent with a 9% fee and warrants for 39,327 shares at $4.2735.
At the time of this announcement, NUWE was trading at $1.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $1.83 to $388.85. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.